Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial.
Glaucoma and Ocular PressureOcular Oncology
Related content
Glaucoma and Ocular PressureOcular Oncology
Eyepass Glaucoma Implant in Open-Angle Glaucoma After Failed Conventional Medical Therapy: Clinical Results of a 5-Year-Follow-up
J Glaucoma.
Wittmann B, Huchzermeyer C, Rejdak R, Reulbach U, Dietlein T, Hohberger B, Jünemann A
doi: 10.1097/IJG.000000000
COMMENTED
Further Publications
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
JAMA Ophthalmol
Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Lee WK, Cheung CMG, Ngah NF, Patalauskaite R, Margaron P, Koh A, EVEREST II Study Group.
doi: 10.1001/jamaophthalmol.2020.2443
Glaucoma and Ocular PressureOcular OncologySurgery and Intervention
Ab Interno Gel Implant for the Treatment of Glaucoma Patients With or Without Prior Glaucoma Surgery - One Year Results
J Glaucoma.
Hengerer FH, Kohnen T, Mueller M, Conrad-Hengerer I
doi: 10.1097/
Glaucoma and Ocular PressureOcular OncologySurgery and Intervention
Short-term to Long-term Results of Ahmed Glaucoma Valve Implantation for Uveitic Glaucoma Secondary to Behçet Disease
J Glaucoma.
Yakin M, Eksioglu U, Sungur G, Satana B, Demirok G, Ornek F
doi: 10.1097/
Cornea and Corneal Diseases
Corneal transplant follow-up study II (CTFS II): a prospective clinical trial to determine the influence of HLA class II matching on corneal transplant rejection: baseline donor and recipient characteristics
Br J Ophthalmol.
Armitage WJ, Winton HL, Jones MNA, Crewe JM, Rogers CA, Tole DM, Dick AD
doi: 10.1136/bjophthalmol-2017-311342.
Uveitis
Incidence and outcome of uveitic glaucoma in eyes with intermediate, posterior or panuveitis followed up to 10 years after randomization to fluocinolone acetonide implant or systemic therapy
Am J Ophthalmol.
Kempen JH, Van Natta ML, Friedman DS, Altaweel MM, Ansari H, Dunn JP, Elner SG, Holbrook JT, Lim LL, Sugar EA, Jabs DA, Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group
doi: 10.1016/j.ajo.2020.06.038.
RECOMMENDED
Further Publications
A Prospective Randomized Trial of Ahmed Glaucoma Drainage Device Implantation With or Without Ologen Collagen Matrix
★ 1
Recommended by
Prof. Dr emer. Josef Flammer, Faculty Member
Ophthalmol Glaucoma
Harizman N, Du J, Tania Tai TY
doi: 10.1016/j.ogla.2020.12.005
Macular Diseases
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
JAMA Ophthalmol.
Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU
doi: 10.1001/jamaophthalmol.
RECOMMENDED
Glaucoma and Ocular PressureSurgery and Intervention
A prospective randomized trial comparing Hydrus and iStent micro-invasive glaucoma glaucoma surgery implants for standalone treatment of open-angle glaucoma: The COMPARE Study
Ophthalmology.
Ahmed IIK, Fea A, Au L, Ang RE, Harasymowycz P, Jampel H, Samuelson TW, Chang DF, Rhee DJ, COMPARE Investigators.
doi: 10.1016/j.ophtha.2019.04.034.